Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis

References

• Ben Hadj M, Bouguerra H, Saffar F, Chelly S, Hechaichi A, Talmoudi K, Bahrini A, Chouki T, Hazgui O, Hannachi N, et al. Observational study of vaccine effectiveness 20years after the introduction of universal hepatitis B vaccination in Tunisia. Vaccine. 2018;36:5858–64. doi:10.1016/j.vaccine.2018.08.038.
   PubMed Web of Science ®Google Scholar
• Costa CI, Delgado IF, Da Costa JAC, De Carvalho RF, Mouta E Júnior SDS, Vianna COA, De Moraes MTB. Establishment and validation of an ELISA for the quantitation of HBsAg in recombinant hepatitis B vaccines. J Virol Methods. 2011;172:32–37. doi:10.1016/j.jviromet.2010.12.010.
   PubMed Web of Science ®Google Scholar
• Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011;53:68–75. doi:10.1093/cid/cir270.
   PubMed Web of Science ®Google Scholar
• Hung HF, Chen TH. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and hepatitis B E Antigen positive prevalence. Vaccine. 2009;27:6770–76. doi:10.1016/j.vaccine.2009.08.082.
   PubMed Web of Science ®Google Scholar
• European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 2000;355:561–65. doi:10.1016/S0140-6736(99)07239-6.
   PubMed Web of Science ®Google Scholar
• Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian Expanded Program on Immunization (EPI): a systematic review and meta-analysis study. Hepat Mon. 2015;15:e23618. doi:10.5812/hepatmon.23618.
   PubMed Web of Science ®Google Scholar
• Garcia D, Porras A, Rico Mendoza A, Alvis N, Navas MC, De La Hoz F, De Neira M, Osorio E, Valderrama JF. Hepatitis B infection control in Colombian Amazon after 15years of hepatitis B vaccination. Effectiveness of birth dose and current prevalence. Vaccine. 2018;36:2721–26. doi:10.1016/j.vaccine.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Liaw Y-F, Chu C-M. Hepatitis B virus infection. Lancet. 2009;373:582–92. doi:10.1016/S0140-6736(09)60207-5.
   PubMed Web of Science ®Google Scholar
• Mirahmadizadeh A, Zahmatkesh S, Kashfi Nezhad M, Sayadi M, Tabatabaee H, Mokhtari A. Vaccination coverage in children of Fars Province, 2017: achievement of global vaccine action plan goals. Sadra Med Sci J. 2018;6:251–60. Persian.
   Google Scholar
• Merat S, Nouraie M, Abolghasemi H, Jamali R, Amini-Kafiabad S, Maghsudlu M, Pourshams A, Malekzadeh R. Seroprevalence and risk factors of hepatitis A virus infection in Iran: a population based study. Arch Iran Med. 2010;13:99.
   PubMed Web of Science ®Google Scholar
• Moghadami M, Dadashpour N, Mokhtari AM, Ebrahimi M, Mirahmadizadeh A. The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study. Braz J Infect Dis. 2019b;23:419–26. doi:10.1016/j.bjid.2019.10.001.
   PubMed Web of Science ®Google Scholar
• Weinberg GA, Szilagyi PG. Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis. 2010;201:1607–10. doi:10.1086/652404.
   PubMed Web of Science ®Google Scholar
• Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, JIT M. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European Vaccine Economics Community. Pharmacoeconomics. 2016;34:227–44. doi:10.1007/s40273-015-0335-2.
   PubMed Web of Science ®Google Scholar
• Haas M. Economic evaluation: a useful research method. Aust J Physiother. 2003;49:85–86. doi:10.1016/S0004-9514(14)60124-0.
   PubMed Web of Science ®Google Scholar
• Griffiths UK, Hutton G, Pascoal EDD. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique. Health Policy Plan. 2005;20:50–59. doi:10.1093/heapol/czi006.
   PubMed Web of Science ®Google Scholar
• Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 2011:1294–306.
   Google Scholar
• Zehtab N, Jafari M, Barooni M, Nakhaee N, Goudarzi R, Larry Zadeh MH. Cost-effectiveness analysis of breast cancer screening in Rural Iran. Asian Pac J Cancer Prev. 2016;17:609–14. doi:10.7314/APJCP.2016.17.2.609.
   PubMedGoogle Scholar
• Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bull World Health Organ. 2007;85:833–42. doi:10.2471/BLT.06.038893.
   PubMed Web of Science ®Google Scholar
• Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ. 2001;10:751–74.
   PubMed Web of Science ®Google Scholar
• Klingler C, Thoumi AI, Mrithinjayam VS. Cost-effectiveness analysis of an additional birth dose of hepatitis B vaccine to prevent perinatal transmission in a medical setting in Mozambique. Vaccine. 2012;31:252–59. doi:10.1016/j.vaccine.2012.08.007.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh A, Khoshnoodi J, Ghorbani S, Hazrati SM, Faraj Mazaheri B, Shokri F. Differential immunogenicity of a recombinant hepatitis B vaccine in Iranian neonates: influence of ethnicity and environmental factors. Iran J Immunol. 2004;1:98–104.
   Google Scholar
• Hahné S, Veldhuijzen I, Wiessing L, Lim T, Salminen M, Van de Laar M. Evidence for the cost-effectiveness of screening for chronic hepatitis B and C among migrant populations: results from a review of the literature. screening. 2013;13:181.
   Google Scholar
• Moghadami M, Dadashpour N, Mokhtari AM, Ebrahimi M, Mirahmadizadeh A. The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study. Braz J Infect Dis. 2019a;23:419–26.
   PubMed Web of Science ®Google Scholar
• Zuckerman JN. Nonresponse to hepatitis B vaccines and the kinetics of anti-HBs production. J. Med. Virol. 1996;50(4):283–88.
   Google Scholar
• Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med. 2008;35:25–32. doi:10.1016/j.amepre.2008.03.028.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J Hepatol. 2003;38:215–22. doi:10.1016/S0168-8278(02)00382-3.
   PubMed Web of Science ®Google Scholar
• Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, et al. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. Hum Vaccin Immunother. 2014;10:2983–91. doi:10.4161/hv.29944.
   PubMed Web of Science ®Google Scholar
• Tu HAT, De Vries R, Woerdenbag HJ, Li SC, Le HH, Van Hulst M, Postma MJ. Cost-effectiveness analysis of hepatitis B immunization in vietnam: application of cost-effectiveness affordability curves in health care decision making. Value Health Reg Issues. 2012;1:7–14. doi:10.1016/j.vhri.2012.03.007.
   PubMedGoogle Scholar
• Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DKH, Ungar WJ, Einarson TR, Sherman M, Heathcote JE, et al. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol. 2012;26:445–51. doi:10.1155/2012/736452.
   PubMed Web of Science ®Google Scholar
• Walker D. Cost and cost-effectiveness guidelines: which ones to use? Health Policy Plan. 2001;16:113–21. doi:10.1093/heapol/16.1.113.
   PubMed Web of Science ®Google Scholar
• Berangi Z, Karami M, Mohammadi Y, Nazarzadeh M, Zahraei SM, Javidrad H, Heidari S. Epidemiological profile of meningitis in Iran before pentavalent vaccine introduction. BMC Pediatr. 2019;19:370. doi:10.1186/s12887-019-1741-y.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press; 2015. https://books.google.co.uk/books?id=lvWACgAAQBAJ
   Google Scholar
• Fox-Rushby J, Cairns J. Economic evaluation. Open University Press: McGraw-Hill Education (UK); 2005.
   Google Scholar
• Prieto L, Sacristan JA. Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes. 2003;1:80. doi:10.1186/1477-7525-1-80.
   PubMedGoogle Scholar
• Lu SQ, Mcghee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine. 2013;31:1864–69. doi:10.1016/j.vaccine.2013.01.020.
   PubMed Web of Science ®Google Scholar
• Siddiqui MR, Gay N, Edmunds WJ, Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine. 2011;29:466–75. doi:10.1016/j.vaccine.2010.10.075.
   PubMed Web of Science ®Google Scholar
• Hall EW, Rosenberg ES, Trigg M, Nelson N, Schillie SJPHR. Cost analysis of single-dose hepatitis B revaccination among infants born to hepatitis B surface antigen-positive mothers and not responding to the initial vaccine series. Public Health Rep. 2018;133(3):338–46.
   Google Scholar
• Tilson L, Thornton L, O’Flanagan D, Johnson H, barry M. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health. 2008;18:275–82. doi:10.1093/eurpub/ckm123.
   PubMed Web of Science ®Google Scholar
• Chinnaratha MA, Kaambwa B, Woodman RJ, Fraser RJ, Wigg AJ. Assessing the clinical and economic impact of increasing treatment uptake in chronic hepatitis B infection using a Markov model. J Gastroenterol Hepatol. 2017;32(7):1370–7.
   PubMed Web of Science ®Google Scholar
• Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, et al. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int. 2016;10(6):924–36.
   PubMed Web of Science ®Google Scholar
• Wiens A, Lenzi L, Venson R, Pedroso ML, Correr CJ, Pontarolo R. Economic evaluation of treatments for chronic hepatitis B. Braz J Infect Dis. 2013;17(4):418–26.
   PubMed Web of Science ®Google Scholar
• Lee D, Park SM. Cost-effectiveness analysis of hepatitis B vaccination strategies to prevent perinatal transmission in North Korea: selective vaccination vs. universal vaccination. PloS One. 2016;11(11):e0165879.
   PubMed Web of Science ®Google Scholar
• Kavosi Z, Zare F, Jafari A, Fattahi MR. Economic burden of hepatitis B virus infection in different stages of disease; a report from southern iran. Middle East J Digest Dis. 2014;6(3):156.
   PubMedGoogle Scholar
• Keshavarz K, Kebriaeezadeh A, Alavian SM, Akbari Sari A, Abedin Dorkoosh F, Keshvari M, et al. Economic burden of hepatitis B virus-related diseases: evidence from iran. Hepat Mon. 2015;15(4):e25854.
   PubMed Web of Science ®Google Scholar
• Adibi P, Rezailashkajani M, Roshandel D, Behrouz N, Ansari S, Somi MH, et al. An economic analysis of premarriage prevention of hepatitis B transmission in Iran. BMC Infect Dis. 2004;4(1):31.
   PubMedGoogle Scholar
• Hajarizadeh B, Rashidian A, Haghdoost A, Alavian S. Estimating the costs of the mass vaccination campaign against hepatitis B in Iranian adolescents. GOVARESH. 2009;14(1):27–34.
   Google Scholar
• Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health. 2008;11(3):527–38.
   PubMed Web of Science ®Google Scholar
• Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13(5):592–600.
   PubMed Web of Science ®Google Scholar
• Edejer T-T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans D, et al. WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
   Google Scholar
• Hutton DW, So SK, Brandeau ML. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology. 2010;51(2):405–14.
   PubMed Web of Science ®Google Scholar